A Five-cohort, Randomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine (SB252263) 300mg When Co-administered With the Artemisinin-based Combination Therapies (ACT) Artemether + Lumefantrine (AL) and Dihydroartemisinin + Piperaquine Tetraphosphate (DHA+PQP)
Phase of Trial: Phase I
Latest Information Update: 20 May 2017
Price : $35 *
At a glance
- Drugs Tafenoquine (Primary) ; Artemether/lumefantrine; Dihydroartemisinin/piperaquine
- Indications Malaria
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 03 Oct 2016 Results published in the Antimicrobial Agents and Chemotherapy.
- 19 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Mar 2015 Planned End Date changed from 1 Mar 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record